Vaso AI Stock Analysis
Want to see VASO full AI Analyst Report?
Vaso (VASO) AI Stock Analysis
Vaso
(Other OTC:VASO)
The overall score of 62 reflects a company with a solid financial foundation but significant operational challenges. The primary positive driver is strong bullish momentum in the stock price, supported by a robust, debt-free balance sheet. These strengths are counterbalanced by the primary risk: a clear downward trend in revenue and profitability that has led to volatile cash flows. The reasonable P/E valuation provides some support but is contingent on a turnaround that is not yet evident in the financial statements.
Vaso (VASO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $50.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 130.64K
- Price to Earnings (P/E)
- 17.3
- Beta (1Y)
- 0.65
- Revenue Growth
- -8.03%
- EPS Growth
- ―
- Country
- US
- Employees
- 282
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Vaso Business Overview & Revenue Model
Company Description
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions...
Vaso Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with minimal debt and growing equity (Score 75). However, the income statement shows declining revenue and severe margin compression (Score 35), and cash flow is volatile with a recent dramatic decline (Score 40). The overall profile is of a well-capitalized company facing significant operational headwinds.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.22M | 89.10M | 86.77M | 81.02M | 80.02M | 75.58M |
| Gross Profit | 51.98M | 54.67M | 52.05M | 50.59M | 48.48M | 43.13M |
| EBITDA | 413.00K | -423.00K | 2.10M | 5.95M | 8.38M | 6.66M |
| Net Income | 2.79M | 1.57M | 951.00K | 4.80M | 11.87M | 6.10M |
Balance Sheet | ||||||
| Total Assets | 85.91M | 88.35M | 82.94M | 75.76M | 72.66M | 52.36M |
| Cash, Cash Equivalents and Short-Term Investments | 38.29M | 35.05M | 26.27M | 25.32M | 20.32M | 6.65M |
| Total Debt | 1.79M | 1.81M | 2.38M | 2.06M | 1.80M | 1.39M |
| Total Liabilities | 56.70M | 58.92M | 55.24M | 48.91M | 49.78M | 41.05M |
| Stockholders Equity | 29.21M | 29.43M | 27.70M | 26.84M | 22.88M | 11.31M |
Cash Flow | ||||||
| Free Cash Flow | 6.90M | 8.35M | 1.83M | 4.57M | 13.85M | 7.40M |
| Operating Cash Flow | 7.86M | 9.27M | 3.28M | 5.30M | 14.42M | 7.82M |
| Investing Cash Flow | -821.00K | -725.00K | 11.73M | -5.66M | -8.42M | -260.00K |
| Financing Cash Flow | -834.00K | 248.00K | -89.00K | -134.00K | -230.00K | -8.33M |
Vaso Risk Analysis
Vaso disclosed 32 risk factors in its most recent earnings report. Vaso reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksVaso Peers Comparison
Overall Rating
- VASO62Neutral
BEAT44Neutral
VSEE41Neutral
HCTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VASO | 62Neutral | $50.91M | 17.29 | 9.68% | ― | -8.03% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| BEAT | 44Neutral | $23.16M | -0.78 | -686.78% | ― | ― | 26.80% |
| VSEE | 41Neutral | $554.18K | -0.01 | -400.87% | ― | -9.31% | 89.42% |
| HCTI | 38Underperform | $3.89M | -0.00 | -56.46% | ― | 116.40% | 99.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VASO | Vaso Corp | 0.29 | 0.17 | 138.33% | |
| HCTI | Healthcare Triangle, Inc. | 3.74 | -2504.26 | -99.85% | |
| BEAT | Heartbeam, Inc. | 0.40 | -1.16 | -74.17% | |
| VSEE | Vsee Health, Inc. | 0.47 | -58.87 | -99.21% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.55 | -0.45 | -44.70% | |
| MGRX | Mangoceuticals, Inc. | 0.18 | -1.29 | -87.50% |
Vaso Corporate Events
Vaso Completes Sale of NetWolves Network Services
NeutralOn July 31, 2026, Vaso Corporation and its subsidiary VasoTechnology, Inc. completed the sale of all issued and outstanding membership interests in NetWolves Network Services LLC to COEO Solutions, LLC under an Equity Purchase Agreement. The cash bas...
Vaso Adds Financial Expert Shaun McMeans to Board
PositiveOn July 23, 2026, Vaso Corporation appointed 64-year-old finance executive Shaun McMeans as a Class III director and member of its audit committee, effective immediately. The move adds a designated financial expert to the board, reinforcing governanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026